KMDA
Strong BuyFull HouseAI neutralKamada Ltd. · Healthcare · Israel · $448M cap · $736K/day traded
$7.94 +2.2% · close 26 Oct · scored 27 Oct
Full House: Strong business, sensible price, market agrees. The rare full house.
Report expected 9 Nov: the next-year EPS estimate has fallen 6.0% over the last 14 weeks.
As of 27 Oct 2026, MoatMap's StockRank for Kamada Ltd. (KMDA) is 84/100, ranked against 24,000+ stocks in 35 markets (Quality 66, Value 61, Momentum 54, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Kamada is an Israeli maker of plasma-derived specialty medicines, including KedRAB, an anti-rabies immunoglobulin sold in the US. It reported record revenue and profit for the first half of 2026 and declared a $0.17 cash dividend. The CDC has reported a clear rise in US rabies exposures and immunoglobulin use, and the company says it has enough supply to meet that demand. The business is profitable and cash-generating. Growth still depends on a small number of products in a niche market, and the evidence of a lasting step-up in earnings is limited.
ABOUT KAMADA LTD.
Read
Kamada Ltd. is an Israeli biopharmaceutical company specializing in the development, manufacture, and commercialization of plasma-derived protein therapeutics for rare diseases and serious conditions. The company's competitive moat stems from its expertise in plasma protein purification and its vertically integrated operations, which encompass plasma collection to commercialization of its specialized orphan drug portfolio for niche patient populations.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 129.3M | 142.5M | 161.0M | 180.5M | 11.7% | 191.8M | 197.6M | 222.6M | 11.1% |
| EPS | -0.05 | 0.17 | 0.25 | 0.35 | 43.5% | 0.38 | 0.48 | 0.58 | 28.4% |
| Shares | 44.8M | 57.5M | 57.5M | 57.7M | +28.7% | 57.7M | — | — | — |
| Debt | 20.6M | 8.8M | 11.1M | 11.6M | -17.5% | 11.8M | — | — | — |
| Equity | 176.0M | 244.0M | 259.5M | 269.1M | 15.2% | — | — | — | — |
| Op CF | 28.6M | 4.3M | 47.6M | 25.5M | -3.7% | 35.8M | — | — | — |
| Inv CF | -3.8M | -5.8M | -10.7M | -9.8M | — | — | — | — | — |
| Fin CF | -9.3M | 22.7M | -13.9M | -18.3M | — | — | — | — | — |
No clear trend: not near its 52-week low, and not in a steady uptrend.
Calmer than 63% of stocks we rank over the past year (35% a year).
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of KMDA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| KMDA | Kamada Ltd.(you) | $448M | 84 | Strong Buy |
| INCR | InterCure Ltd. | $68M | 33 | Sell |
| TEVA | Teva Pharmaceutical Industries Limited | $46.0B | 61 | Hold |
| INMD | InMode Ltd. | $804M | 93 | Strong Buy |
| CGEN | Compugen Ltd. | $184M | 90 | Strong Buy |
| 1696.HK | Sisram Medical Ltd | $108M | 86 | Strong Buy |
| BWAY | BrainsWay Ltd. | $453M | 50 | Hold |
| ENTX | Entera Bio Ltd. | $508M | 20 | Sell |
| SLGL | Sol-Gel Technologies Ltd. | $227M | 24 | Sell |
| DRTS | Alpha Tau Medical Ltd. | $1.2B | 25 | Sell |
Peer medians: ROE -13.8% · P/E 9.7x · Gross margin 54.9%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.